Health Insurance - Prescription Insulin Drugs - Limits on Copayment and Coinsurance (Insulin Cost Reduction Act)
Sponsor: Clarence K. Lam (District 12)Committee: FinanceSubject: Health - InsuranceStatus: Vetoed by the Governor (Duplicative) (as of Nov 15, 2022)
What this bill does
Official synopsis
Requiring insurers, nonprofit health service plans, and health maintenance organizations to limit the amount a covered individual is required to pay in copayments or coinsurance for a covered prescription insulin drug to not more than $30 for a 30-day supply.
AI analysis is off. Set ANTHROPIC_API_KEY to enable summaries, pros and cons, and questions.
Analysis reads the bill text, the fiscal note, and the witness list. It is generated by Claude and reviewed by nobody, so check the source documents before you rely on it.
Testimony (24)
MGA witness listFAV 20FavorableFWA 1Favorable with amendmentsUNF 1UnfavorableINFO 2Information only
Organizations on record
Registered lobbyists who testified
FAVKirk Robins, CatherineMaryland Citizens' Health Initiative, Inc.Registered for: Maryland Citizens' Health Initiative, Inc.
FAVElliott, RobynRegistered for: American Association for Marriage and Family Therapists; Amica Center for Immigrant Rights; CareForth; Chase Brexton Health System; Coordinating Center, The; Diabetes Patient Advocacy Coalition…
FAVKauffman, DannaRegistered for: Amazon.com Services, LLC; American Association of Dental Boards c/o Commission on Dental Competency Assessments; Baltimore Gas and Electric Company; Behavioral Health System Baltimore; City of Rockville; Community Behavioral Health Association of Maryland…
UNFCelentano, MatthewFunk & Bolton, P.A.Registered for: 38 Degrees North; Advanced Energy United; Alliance of Maryland Dental Plans; Allstate Insurance Company; America's Health Insurance Plans; American Council of Life Insurers…
